Enke Grabhorn
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Enke Grabhorn has a total of 69 co-authors. Here are the top co-authors by number of shared publications:
Uta Herden
7 shared publicationsFlorian Brinkert
Department of Pediatrics University Hospital Hamburg‐Eppendorf Hamburg Germany
5 shared publicationsLutz Fischer
Department of Hepatobiliary Surgery and Transplantation University Medical Center Hamburg‐Eppendorf Hamburg Germany
4 shared publicationsAndrea Briem-Richter
3 shared publications- Florian Brinkert
Department of Pediatric Gastroenterology and Hepatology, University Clinic Hamburg-Eppendorf, Hamburg, Germany
3 shared publications Rainer Ganschow
Department of Pediatrics, University Hospital Bonn, Germany
3 shared publications
Latest Publications
- Open Access
Mild Crigler–Najjar Syndrome with Progressive Liver Disease—A Multicenter Retrospective Cohort Study
Crigler–Najjar Syndrome (CNS) with residual activity of UDP-glucuronosyltransferase 1A1 (UGT1A1) and no need for daily phototherapy is called mild Crigler–Najjar Syndrome. Most of these patients need medical treatment for enzyme induction (phenobarbital) to lower blood levels of unconjugated bilirubin (UCB). Apart from this, no long-term problems have been described so far. The phenotype of patients with the homozygous pathogenic variant c.115C>G p.(His39Asp) in UGT1A1 is described as variable. Clinical observations of our patients led to the assumption that patients with variant c.115C>G have a mild CNS phenotype while having a high risk of developing progressive liver disease. For mild CNS disease, progressive liver disease has not been described so far. Therefore, we conducted a retrospective multicenter analysis of 14 patients with this particular variant, aiming for better characterization of this variant. We could confirm that patients with variant c.115C>G have a high risk of progressive liver disease (seven of fourteen), which increases with age despite having a very mild CNS phenotype. Earlier predictors and causes for an unfavorable disease course are not detectable, but close follow-up could identify patients with progressive liver disease at the beginning. In conclusion, these patients need close and specialized follow-up. Our study questions whether fibrosis in the CNS is really driven by high amounts of UCB or phototherapy.
Open AccessMild Crigler–Najjar Syndrome with Progressive Liver Disease—A Multicenter Retrospective Cohort Study
Crigler–Najjar Syndrome (CNS) with residual activity of UDP-glucuronosyltransferase 1A1 (UGT1A1) and no need for daily phototherapy is called mild Crigler–Najjar Syndrome. Most of these patients need medical treatment for enzyme induction (phenobarbital) to lower blood levels of unconjugated bilirubin (UCB). Apart from this, no long-term problems have been described so far. The phenotype of patients with the homozygous pathogenic variant c.115C>G p.(His39Asp) in UGT1A1 is described as variable. Clinical observations of our patients led to the assumption that patients with variant c.115C>G have a mild CNS phenotype while having a high risk of developing progressive liver disease. For mild CNS disease, progressive liver disease has not been described so far. Therefore, we conducted a retrospective multicenter analysis of 14 patients with this particular variant, aiming for better characterization of this variant. We could confirm that patients with variant c.115C>G have a high risk of progressive liver disease (seven of fourteen), which increases with age despite having a very mild CNS phenotype. Earlier predictors and causes for an unfavorable disease course are not detectable, but close follow-up could identify patients with progressive liver disease at the beginning. In conclusion, these patients need close and specialized follow-up. Our study questions whether fibrosis in the CNS is really driven by high amounts of UCB or phototherapy.
- Open Access
Experience with the mTOR Inhibitor Everolimus in Pediatric Liver Graft Recipients
Introduction: Immunosuppression after pediatric liver transplantation remains a major challenge. MTOR inhibitors provide a promising therapeutic approach in combination with reduced CNI after transplantation. However, there are still few data regarding their use in children. Patients: We analyzed 37 patients with a median age of 10 years, who received Everolimus for one or more of the following indications: I = chronic graft dysfunction (n = 22); II = progressive renal impairment (n = 5); III = non-tolerable side effects with previous immunosuppressive medication (n = 6); and IV = malignancies (n = 10). The median follow-up time was 36 months. Results: Patient survival was 97%, and graft survival 84%, respectively. Stabilization of graft function was observed in 59% in subgroup 1, with 18.2% ultimately requiring retransplantation. No patient in subgroup IV developed recurrence of his primary tumor or PTLD by the endpoint of the study. Side effects were observed in 67.5% of the study patients, with infections being the most frequent (n = 20; 54.1%). There were no relevant effects on growth and development. Conclusion: Everolimus seems to be a treatment option in selected pediatric liver graft recipients for whom other regimens are not suitable. Overall, the efficacy was good and the side effect profile appeared to be acceptable.
Open AccessExperience with the mTOR Inhibitor Everolimus in Pediatric Liver Graft Recipients
Introduction: Immunosuppression after pediatric liver transplantation remains a major challenge. MTOR inhibitors provide a promising therapeutic approach in combination with reduced CNI after transplantation. However, there are still few data regarding their use in children. Patients: We analyzed 37 patients with a median age of 10 years, who received Everolimus for one or more of the following indications: I = chronic graft dysfunction (n = 22); II = progressive renal impairment (n = 5); III = non-tolerable side effects with previous immunosuppressive medication (n = 6); and IV = malignancies (n = 10). The median follow-up time was 36 months. Results: Patient survival was 97%, and graft survival 84%, respectively. Stabilization of graft function was observed in 59% in subgroup 1, with 18.2% ultimately requiring retransplantation. No patient in subgroup IV developed recurrence of his primary tumor or PTLD by the endpoint of the study. Side effects were observed in 67.5% of the study patients, with infections being the most frequent (n = 20; 54.1%). There were no relevant effects on growth and development. Conclusion: Everolimus seems to be a treatment option in selected pediatric liver graft recipients for whom other regimens are not suitable. Overall, the efficacy was good and the side effect profile appeared to be acceptable.
- Open Access
- 24 August 2021
- Published by Wiley in Pediatric Transplantation
- Vol. 25 (8) , e14121
Psychosocial situation, adherence, and utilization of video consultation in young adult long‐term pediatric liver transplant recipients during COVID‐19 pandemic
Background: Young adults who underwent liver transplantation in childhood (YALTs) are highly vulnerable to non‐adherent behavior and psychosocial problems. During the COVID‐19 pandemic, special efforts may be necessary to maintain contact with these patients and offer support. This can be achieved through the use of telemedicine. The study's objective was to assess adherence and the psychosocial situation of YALTs during the COVID‐19 pandemic in Germany and to evaluate the utilization of video consultations.Methods: In May 2020, a questionnaire was sent to YALTs treated at the Hamburg University Transplant Center, accompanied by the offer of video appointments with the attending physician. The questionnaire included the Generalized Anxiety Disorder Scale 7, the Patient Health Questionnaire 2, and questions compiled by the authors.Results: Of 98 YALTs, 12% used the video consultation, while 65% had an in‐person appointment. The 56 patients who completed the questionnaire did not report reduced medication adherence during the pandemic, but 40% missed follow‐up visits with their primary care physician or check‐up laboratory tests. About 70% of YALTs were afraid to visit their physician and the transplant center, and 34% were afraid of a SARS‐CoV‐2 infection. Mental health and well‐being were unimpaired.Conclusions: During the COVID‐19 pandemic, YALTs in our study did not show an increased need for psychosocial support, but a majority were afraid to attend medical appointments, and 40% reported lower appointment adherence. Acceptance of video consultations was lower than expected. The reasons for this need to be further investigated in order to optimize care.
- 24 August 2021
- Published by Wiley in Pediatric Transplantation
- Vol. 25 (8) , e14121
Open AccessPsychosocial situation, adherence, and utilization of video consultation in young adult long‐term pediatric liver transplant recipients during COVID‐19 pandemic
Background: Young adults who underwent liver transplantation in childhood (YALTs) are highly vulnerable to non‐adherent behavior and psychosocial problems. During the COVID‐19 pandemic, special efforts may be necessary to maintain contact with these patients and offer support. This can be achieved through the use of telemedicine. The study's objective was to assess adherence and the psychosocial situation of YALTs during the COVID‐19 pandemic in Germany and to evaluate the utilization of video consultations.Methods: In May 2020, a questionnaire was sent to YALTs treated at the Hamburg University Transplant Center, accompanied by the offer of video appointments with the attending physician. The questionnaire included the Generalized Anxiety Disorder Scale 7, the Patient Health Questionnaire 2, and questions compiled by the authors.Results: Of 98 YALTs, 12% used the video consultation, while 65% had an in‐person appointment. The 56 patients who completed the questionnaire did not report reduced medication adherence during the pandemic, but 40% missed follow‐up visits with their primary care physician or check‐up laboratory tests. About 70% of YALTs were afraid to visit their physician and the transplant center, and 34% were afraid of a SARS‐CoV‐2 infection. Mental health and well‐being were unimpaired.Conclusions: During the COVID‐19 pandemic, YALTs in our study did not show an increased need for psychosocial support, but a majority were afraid to attend medical appointments, and 40% reported lower appointment adherence. Acceptance of video consultations was lower than expected. The reasons for this need to be further investigated in order to optimize care.
- Open Access
- 27 June 2021
- Published by Baishideng Publishing Group Inc. in World Journal of Hepatology
- Vol. 13 (6) , 673-685
Impact of donor-specific antibodies on long-term graft survival with pediatric liver transplantation
Impact of donor-specific antibodies on long-term graft survival with pediatric liver transplantation
- 27 June 2021
- Published by Baishideng Publishing Group Inc. in World Journal of Hepatology
- Vol. 13 (6) , 673-685
Open AccessImpact of donor-specific antibodies on long-term graft survival with pediatric liver transplantation
Impact of donor-specific antibodies on long-term graft survival with pediatric liver transplantation
- Open Access
- 27 March 2021
- Published by Frontiers Media SA in Transplant International
- Vol. 34 (7) , 1251-1260
Short‐ and long‐term results of liver transplantation according to age at transplant: a single‐center experience of 351 children
Background Pediatric liver transplantation (PLT) has very good results at experienced transplant centers. However, there is still an ongoing discussion about inferior outcomes, especially in young infants. The aim of this retrospective study was to evaluate outcomes of infants compared to older recipients in a single center over 20 years. Patients and methods We conducted a retrospective study of children who received liver transplants at our center between 1991 and 2011. Only patients without other limiting organ involvement were included and compared according to age. Results The inclusion criteria were fulfilled by 351 patients (173 versus 178). The most common indication in both groups was biliary atresia (82.1% versus 49.4%). The 1‐, 5‐ and 10‐year patient survivals were 93.8%/91.8%/91.1% and 93%/90.8%/90.1%, and the graft survivals were 90.4%/83.5%/79.6% and 89.4%/81.8%/77.5%, respectively. Complications such as postoperative bleeding, biliary complications or perfusion impairment occurred more often in infants. Leading indications for retransplantation (vascular complications/primary nonfunction) and leading causes of death (sepsis/multiorgan failure) were the same in both groups. Significant predictors for patient loss were decade of transplantation, retransplantation, postoperative bleeding and infections for infants. Predictors for graft loss were bowel perforation, arterial thrombosis and age > 12 months. Conclusion Children can have excellent results, independent of age at PLT.
- 27 March 2021
- Published by Frontiers Media SA in Transplant International
- Vol. 34 (7) , 1251-1260
Open AccessShort‐ and long‐term results of liver transplantation according to age at transplant: a single‐center experience of 351 children
Background Pediatric liver transplantation (PLT) has very good results at experienced transplant centers. However, there is still an ongoing discussion about inferior outcomes, especially in young infants. The aim of this retrospective study was to evaluate outcomes of infants compared to older recipients in a single center over 20 years. Patients and methods We conducted a retrospective study of children who received liver transplants at our center between 1991 and 2011. Only patients without other limiting organ involvement were included and compared according to age. Results The inclusion criteria were fulfilled by 351 patients (173 versus 178). The most common indication in both groups was biliary atresia (82.1% versus 49.4%). The 1‐, 5‐ and 10‐year patient survivals were 93.8%/91.8%/91.1% and 93%/90.8%/90.1%, and the graft survivals were 90.4%/83.5%/79.6% and 89.4%/81.8%/77.5%, respectively. Complications such as postoperative bleeding, biliary complications or perfusion impairment occurred more often in infants. Leading indications for retransplantation (vascular complications/primary nonfunction) and leading causes of death (sepsis/multiorgan failure) were the same in both groups. Significant predictors for patient loss were decade of transplantation, retransplantation, postoperative bleeding and infections for infants. Predictors for graft loss were bowel perforation, arterial thrombosis and age > 12 months. Conclusion Children can have excellent results, independent of age at PLT.
- Open Access
- 5 February 2021
- Published by Wiley in Clinical Transplantation
- Vol. 35 (4) , e14219
Outcome of liver transplantation and prevalence of liver fibrosis in Crigler‐Najjar syndrome
Introduction: Crigler‐Najjar syndrome (CNS) is a rare inherited disorder that is characterized by high levels of non‐hemolytic, unconjugated hyperbilirubinemia leading to brain damage and even death. Liver transplantation (LT) can correct the metabolic defect, but there are little data regarding LT in this patient cohort. The liver parenchyma has been considered to be structurally normal in CNS, but there is growing evidence of clinically silent but histologically significant fibrosis in CNS patients.Patients and methods: We included 13 patients in our retrospective study who underwent LT at our center. Patient survival, graft function, and long‐term complications were evaluated over a median follow‐up period of 10 years (range: 1–16 years). In addition, the prevalence of histologically relevant fibrosis was characterized.Results: The overall survival among our LT patients was 100%. The graft survival was only 61.5%. During the follow‐up period, 5 LT patients had to undergo retransplantation. More than 45% of our patients showed histological signs of fibrosis.Conclusion: LT remains the only definite therapeutic option for severe CNS but needs to be considered thoroughly regarding the clinical risk‐benefit‐ratio and impact on quality of life. Furthermore, hepatic parenchymal injury needs to be considered while evaluating future therapeutic options for CNS.
- 5 February 2021
- Published by Wiley in Clinical Transplantation
- Vol. 35 (4) , e14219
Open AccessOutcome of liver transplantation and prevalence of liver fibrosis in Crigler‐Najjar syndrome
Introduction: Crigler‐Najjar syndrome (CNS) is a rare inherited disorder that is characterized by high levels of non‐hemolytic, unconjugated hyperbilirubinemia leading to brain damage and even death. Liver transplantation (LT) can correct the metabolic defect, but there are little data regarding LT in this patient cohort. The liver parenchyma has been considered to be structurally normal in CNS, but there is growing evidence of clinically silent but histologically significant fibrosis in CNS patients.Patients and methods: We included 13 patients in our retrospective study who underwent LT at our center. Patient survival, graft function, and long‐term complications were evaluated over a median follow‐up period of 10 years (range: 1–16 years). In addition, the prevalence of histologically relevant fibrosis was characterized.Results: The overall survival among our LT patients was 100%. The graft survival was only 61.5%. During the follow‐up period, 5 LT patients had to undergo retransplantation. More than 45% of our patients showed histological signs of fibrosis.Conclusion: LT remains the only definite therapeutic option for severe CNS but needs to be considered thoroughly regarding the clinical risk‐benefit‐ratio and impact on quality of life. Furthermore, hepatic parenchymal injury needs to be considered while evaluating future therapeutic options for CNS.
- Open Access
- 25 January 2021
- Published by LIDSEN Publishing Inc in OBM Transplantation
- Vol. 05 (01) , 1-15
Malignancies and Pediatric Liver Transplantation: Promising Management with the mTOR-inhibitor Everolimus
Some malignancies such as hepatoblastoma may be an indication for liver transplantation (LT) or some, for example, post-transplant lymphoproliferative disease (PTLD) may develop after successful LT. An immunosuppressive therapy after LT can promote the recurrence of the primary malignancy. The mammalian target-of-rapamycin inhibitors (mTORi) are immunosuppressive agents with anti-tumor properties. We examined the impact of everolimus (EVL) together with calcineurin inhibitors on allograft outcome and patient survival in pediatric LT (PLT) with various tumors. This retrospective study included eleven liver-transplanted pediatric patients who received EVL after LT. The reason for adding an mTOR inhibitor was the neoplastic disease, either leading to LT (n = 7) or PTLD that developed after LT under immunosuppression (n = 3). The median age at the start of therapy was four years (range: seven months- 18 years); the median follow-up was 3 (range: 1 - 5 years). The primary endpoints were recurrence or metastasis of the primary tumor, uncontrolled PTLD, or death. Graft function and potential side effects were documented. Both patient survival and graft survival rates for the observation period were 100%. No patient developed recurrence or reported metastatic disease of the primary tumor. Liver function test results remained normal during the study period in 8 out of 11 patients. Three patients developed elevated liver enzymes that resolved over time. All the patients received EVL either as monotherapy (n = 2) or in combination with cyclosporine A (n = 7) or tacrolimus (n = 2). Typical side effects documented were recurrent infections (n = 8), stomatitis (n = 5), and cytopenia (n = 2), and medication was temporarily interrupted in one patient. Although the patient cohort was small, our results support the use of EVL in patients with tumor occurrence in the context of pediatric LT. No cases of recurrence or metastases were reported during the follow-up period after LT; sufficient immunosuppression was maintained. The side effect profile appeared acceptable. A longer follow-up in more number of patients is necessary to confirm these preliminary data.
- 25 January 2021
- Published by LIDSEN Publishing Inc in OBM Transplantation
- Vol. 05 (01) , 1-15
Open AccessMalignancies and Pediatric Liver Transplantation: Promising Management with the mTOR-inhibitor Everolimus
Some malignancies such as hepatoblastoma may be an indication for liver transplantation (LT) or some, for example, post-transplant lymphoproliferative disease (PTLD) may develop after successful LT. An immunosuppressive therapy after LT can promote the recurrence of the primary malignancy. The mammalian target-of-rapamycin inhibitors (mTORi) are immunosuppressive agents with anti-tumor properties. We examined the impact of everolimus (EVL) together with calcineurin inhibitors on allograft outcome and patient survival in pediatric LT (PLT) with various tumors. This retrospective study included eleven liver-transplanted pediatric patients who received EVL after LT. The reason for adding an mTOR inhibitor was the neoplastic disease, either leading to LT (n = 7) or PTLD that developed after LT under immunosuppression (n = 3). The median age at the start of therapy was four years (range: seven months- 18 years); the median follow-up was 3 (range: 1 - 5 years). The primary endpoints were recurrence or metastasis of the primary tumor, uncontrolled PTLD, or death. Graft function and potential side effects were documented. Both patient survival and graft survival rates for the observation period were 100%. No patient developed recurrence or reported metastatic disease of the primary tumor. Liver function test results remained normal during the study period in 8 out of 11 patients. Three patients developed elevated liver enzymes that resolved over time. All the patients received EVL either as monotherapy (n = 2) or in combination with cyclosporine A (n = 7) or tacrolimus (n = 2). Typical side effects documented were recurrent infections (n = 8), stomatitis (n = 5), and cytopenia (n = 2), and medication was temporarily interrupted in one patient. Although the patient cohort was small, our results support the use of EVL in patients with tumor occurrence in the context of pediatric LT. No cases of recurrence or metastases were reported during the follow-up period after LT; sufficient immunosuppression was maintained. The side effect profile appeared acceptable. A longer follow-up in more number of patients is necessary to confirm these preliminary data.
- 9 October 2019
- Published by Wiley in Clinical Transplantation
- Vol. 33 (10) , e13687
Impact on the hepatic flow velocity after pediatric combined liver‐kidney transplantation compared to isolated pediatric liver transplantation—A matched‐pair analysis
Background: Combined liver‐kidney transplantation (CLKT) in children is still a rarely performed procedure. Our aim was to analyze the effect of the simultaneous transplantation of the kidney in pediatric CLKT on the liver graft flow velocity, and vascular complications compared to singular liver transplantation (LTX) in children.Methods: All pediatric CLKT performed at our institution from 1998 to 2016 were matched with singular LTX and retrospectively analyzed.Results: Overall 30 CLKT were performed in 28 children (median age 8 years, range 1‐16) and matched with 30 children undergoing singular LTX (median age 7.9 years, range 1‐16). No significant differences were found concerning the systolic peak flow velocity of the hepatic artery (HA) or the resistance index (RI). Vascular complications of the hepatic vessels occurred in 16.7% (CLKT) and 6.7% (LTX). The 1‐/5‐ and 10‐year patient survival was 93.3%/93.3% and 93.3% (CLKT) and 100%/100% and 92.9% (LTX). 1‐/5‐and 10‐year liver graft survival was 76.7%/73.2% and 73.2% (CLKT) and 84.4%/75.9% and 69.6% (LTX).Conclusion: The simultaneous transplantation of the kidney in CLKT had no negative impact on hepatic flow velocity or vascular complications. Frequent Doppler ultrasound examinations, accurate volume management, and avoidance of abdominal pressure might be an explanation for the results and an excellent graft‐ and patient survival.
- 9 October 2019
- Published by Wiley in Clinical Transplantation
- Vol. 33 (10) , e13687
Impact on the hepatic flow velocity after pediatric combined liver‐kidney transplantation compared to isolated pediatric liver transplantation—A matched‐pair analysis
Background: Combined liver‐kidney transplantation (CLKT) in children is still a rarely performed procedure. Our aim was to analyze the effect of the simultaneous transplantation of the kidney in pediatric CLKT on the liver graft flow velocity, and vascular complications compared to singular liver transplantation (LTX) in children.Methods: All pediatric CLKT performed at our institution from 1998 to 2016 were matched with singular LTX and retrospectively analyzed.Results: Overall 30 CLKT were performed in 28 children (median age 8 years, range 1‐16) and matched with 30 children undergoing singular LTX (median age 7.9 years, range 1‐16). No significant differences were found concerning the systolic peak flow velocity of the hepatic artery (HA) or the resistance index (RI). Vascular complications of the hepatic vessels occurred in 16.7% (CLKT) and 6.7% (LTX). The 1‐/5‐ and 10‐year patient survival was 93.3%/93.3% and 93.3% (CLKT) and 100%/100% and 92.9% (LTX). 1‐/5‐and 10‐year liver graft survival was 76.7%/73.2% and 73.2% (CLKT) and 84.4%/75.9% and 69.6% (LTX).Conclusion: The simultaneous transplantation of the kidney in CLKT had no negative impact on hepatic flow velocity or vascular complications. Frequent Doppler ultrasound examinations, accurate volume management, and avoidance of abdominal pressure might be an explanation for the results and an excellent graft‐ and patient survival.
- Open Access
- 25 July 2019
- Published by Wiley in Clinical Transplantation
- Vol. 33 (10) , e13676
Tissue inhibitor of metalloproteinase 1 and AST‐to‐Platelet Ratio Index as noninvasive biomarkers predict allograft fibrosis after pediatric liver transplantation
Background: Assessing liver fibrosis in patients after liver transplantation is still largely dependent on liver biopsy. Especially in children, noninvasive methods are of utmost importance. We evaluated tissue inhibitor of metalloproteinase 1 (TIMP1) and AST‐to‐Platelet Ratio Index (APRI) and their potential as serum biomarkers to predict liver allograft fibrosis (LAF) in a pediatric cohort.Methods: In this retrospective, observational study, we analyzed 91 protocol liver biopsy specimens from 73 children after pediatric liver transplantation (PLT) and compared histological stage of liver fibrosis using LAF Score (LAFSc) and Ishak Score (IshakSc) to TIMP1‐serum concentration and APRI using ROC analysis.Results: In our cohort, TIMP1 and APRI reliably predict LAF. Depending on the histological scoring system, cutoff values for TIMP1 were 328 ng/mL (IshakSc ≥ IV) and 351 ng/mL (LAFSc ≥ 5) with AUC of 0.86 and 0.98. The cutoff for APRI was 0.8 with AUC of 0.87 (IshakSc ≥ IV) and 0.94 (LAFSc ≥ 5). Using LAFSc, TIMP1 and APRI showed excellent diagnostic accuracy to detect severe LAF (LAFSc ≥ 5) with PPV of ≥ 90% and NPV of 100%.Conclusion: TIMP1 and APRI are accurate biomarkers to predict severe LAF in children. The use of TIMP1 and APRI will not replace but complement liver biopsies after PLT to further improve our understanding of each individual patient.
- 25 July 2019
- Published by Wiley in Clinical Transplantation
- Vol. 33 (10) , e13676
Open AccessTissue inhibitor of metalloproteinase 1 and AST‐to‐Platelet Ratio Index as noninvasive biomarkers predict allograft fibrosis after pediatric liver transplantation
Background: Assessing liver fibrosis in patients after liver transplantation is still largely dependent on liver biopsy. Especially in children, noninvasive methods are of utmost importance. We evaluated tissue inhibitor of metalloproteinase 1 (TIMP1) and AST‐to‐Platelet Ratio Index (APRI) and their potential as serum biomarkers to predict liver allograft fibrosis (LAF) in a pediatric cohort.Methods: In this retrospective, observational study, we analyzed 91 protocol liver biopsy specimens from 73 children after pediatric liver transplantation (PLT) and compared histological stage of liver fibrosis using LAF Score (LAFSc) and Ishak Score (IshakSc) to TIMP1‐serum concentration and APRI using ROC analysis.Results: In our cohort, TIMP1 and APRI reliably predict LAF. Depending on the histological scoring system, cutoff values for TIMP1 were 328 ng/mL (IshakSc ≥ IV) and 351 ng/mL (LAFSc ≥ 5) with AUC of 0.86 and 0.98. The cutoff for APRI was 0.8 with AUC of 0.87 (IshakSc ≥ IV) and 0.94 (LAFSc ≥ 5). Using LAFSc, TIMP1 and APRI showed excellent diagnostic accuracy to detect severe LAF (LAFSc ≥ 5) with PPV of ≥ 90% and NPV of 100%.Conclusion: TIMP1 and APRI are accurate biomarkers to predict severe LAF in children. The use of TIMP1 and APRI will not replace but complement liver biopsies after PLT to further improve our understanding of each individual patient.
- 26 December 2018
- Published by Wiley in Pediatric Transplantation
- Vol. 23 (1) , e13331
Fatigue in pediatric liver transplant recipients and its impact on their quality of life
The aim of the study was to investigate the occurrence of fatigue in 100 pediatric liver transplant recipients aged 2‐18 years and its impact on their health‐related quality of life (HRQL). HRQL and fatigue were measured using the PedsQL 4.0 Inventory and the PedsQL Multidimensional Fatigue Scale, which encompasses three subscales: general fatigue, sleep/rest fatigue, and cognitive fatigue. The impact of the different domains of fatigue and of clinical and sociodemographic factors on the HRQL was identified with stepwise multiple regression analyses. Parent proxy‐reports were available for all 100 participants (2‐18 years), and child self‐reports were available for 71 patients (8‐18 years). Across all domains, participants and their parents reported significantly more fatigue than healthy peers in a large PedsQL validation study. Thirty‐seven percent of patients and 57% of parents scored clinically relevant levels of fatigue. In the multiple regression analyses, none of the clinical and sociodemographic factors contributed to the HRQL for child self‐report. Only general and cognitive fatigue were significant predictors of patients' HRQL, explaining 66% of the variance in the PedsQL total score. For parent proxy‐report, general and cognitive fatigue also significantly predicted child's HRQL. Further predictors were child's age and family income. The regression model explained 65% of the variance. These findings demonstrate the importance of assessing fatigue during regular follow‐up examinations. Further research is urgently needed to better understand the underlying mechanisms of fatigue. Improvement of fatigue symptoms is essential for better HRQL, for cognitive functioning, and for school achievement.
- 26 December 2018
- Published by Wiley in Pediatric Transplantation
- Vol. 23 (1) , e13331
Fatigue in pediatric liver transplant recipients and its impact on their quality of life
The aim of the study was to investigate the occurrence of fatigue in 100 pediatric liver transplant recipients aged 2‐18 years and its impact on their health‐related quality of life (HRQL). HRQL and fatigue were measured using the PedsQL 4.0 Inventory and the PedsQL Multidimensional Fatigue Scale, which encompasses three subscales: general fatigue, sleep/rest fatigue, and cognitive fatigue. The impact of the different domains of fatigue and of clinical and sociodemographic factors on the HRQL was identified with stepwise multiple regression analyses. Parent proxy‐reports were available for all 100 participants (2‐18 years), and child self‐reports were available for 71 patients (8‐18 years). Across all domains, participants and their parents reported significantly more fatigue than healthy peers in a large PedsQL validation study. Thirty‐seven percent of patients and 57% of parents scored clinically relevant levels of fatigue. In the multiple regression analyses, none of the clinical and sociodemographic factors contributed to the HRQL for child self‐report. Only general and cognitive fatigue were significant predictors of patients' HRQL, explaining 66% of the variance in the PedsQL total score. For parent proxy‐report, general and cognitive fatigue also significantly predicted child's HRQL. Further predictors were child's age and family income. The regression model explained 65% of the variance. These findings demonstrate the importance of assessing fatigue during regular follow‐up examinations. Further research is urgently needed to better understand the underlying mechanisms of fatigue. Improvement of fatigue symptoms is essential for better HRQL, for cognitive functioning, and for school achievement.